| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.390 | Biomarker | disease | BEFREE | The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. | 29569717 | 2018 | ||||
|
0.390 | Biomarker | disease | BEFREE | Dendritic cells educated by FASN<sup>high</sup> OvCa ascites are defective in their ability to present antigens and prime T cells. | 30619288 | 2018 | ||||
|
0.390 | Biomarker | disease | BEFREE | Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. | 25302649 | 2015 | ||||
|
0.390 | AlteredExpression | disease | BEFREE | Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. | 25947066 | 2015 | ||||
|
0.390 | Biomarker | disease | BEFREE | These findings suggest that FASN plays a critical role in the peritoneal metastasis of ovarian cancer. | 24979135 | 2014 | ||||
|
0.390 | AlteredExpression | disease | BEFREE | The lipogenic enzyme fatty acid synthase (FASN) is overexpressed in approximately 80% of ovarian carcinomas. | 21970855 | 2011 | ||||
|
0.390 | Biomarker | disease | CTD_human | Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis. | 21442130 | 2011 | ||||
|
0.390 | Biomarker | disease | BEFREE | The study suggests that molecular targeting of FAS and FAK by HO-3867 may be a potential strategy for ovarian cancer therapy. | 20713491 | 2010 | ||||
|
0.390 | AlteredExpression | disease | BEFREE | Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. | 15806173 | 2005 | ||||
|
0.390 | AlteredExpression | disease | BEFREE | Here, we have identified a molecular link between FAS and HER2 (erbB-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers. | 15235125 | 2004 |